{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T12:06:16Z","timestamp":1765713976209,"version":"build-2065373602"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jaut.2021.102687","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T02:50:44Z","timestamp":1626403844000},"page":"102687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-2162","authenticated-orcid":false,"given":"Athanasios-Dimitrios","family":"Bakasis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clio P.","family":"Mavragani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriaki A.","family":"Boki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios G.","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panayiotis G.","family":"Vlachoyiannopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-4035","authenticated-orcid":false,"given":"Ioanna E.","family":"Stergiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotini N.","family":"Skopouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralampos M.","family":"Moutsopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2021","series-title":"WHO Coronavirus (COVID-19) Dashboard","key":"10.1016\/j.jaut.2021.102687_bib1"},{"key":"10.1016\/j.jaut.2021.102687_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217615","article-title":"What is the true incidence of COVID-19 in patients with rheumatic diseases?","volume":"80","author":"Favalli","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib3","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/annrheumdis-2020-217763","article-title":"Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases","volume":"79","author":"Pablos","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib4","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/annrheumdis-2020-218296","article-title":"Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study","volume":"79","author":"Pablos","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib5","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keaa694","article-title":"COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population","volume":"60","author":"Murray","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2021.102687_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","article-title":"COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","volume":"38","author":"Sarzi-Puttini","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2021.102687_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10875-020-00927-y","article-title":"The impact of immunosuppression and autoimmune disease on severe outcomes in patients hospitalized with COVID-19","volume":"41","author":"Monreal","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jaut.2021.102687_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102506","article-title":"Autoinflammatory and autoimmune conditions at the crossroad of COVID-19","volume":"114","author":"Rodr\u00edguez","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102687_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17703-6","article-title":"Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion","volume":"11","author":"Simon","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2021.102687_bib10","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed [4\/2\/2021]."},{"key":"10.1016\/j.jaut.2021.102687_bib11","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.49.2000790","article-title":"Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March 2020","volume":"25","author":"Riccardo","year":"2020","journal-title":"Euro Surveill."},{"key":"10.1016\/j.jaut.2021.102687_bib12","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.41456","article-title":"COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes","volume":"72","author":"Haberman","year":"2020","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2021.102687_bib13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib14","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1136\/annrheumdis-2020-218054","article-title":"Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases","volume":"79","author":"Nu\u00f1o","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102613","article-title":"Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies - a Danish population-based cohort study","volume":"118","author":"Attauabi","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102687_bib16","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/annrheumdis-2020-217888","article-title":"Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US \u2018hot spot\u2019","volume":"79","author":"D'Silva","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib17","article-title":"COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs","author":"Ansarin","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib18","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S2665-9913(20)30169-7","article-title":"COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study","volume":"2","author":"Fredi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.jaut.2021.102687_bib19","first-page":"748","article-title":"COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19)","volume":"38","author":"Scir\u00e8","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2021.102687_bib20","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2020-217984","article-title":"Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Freites Nu\u00f1ez","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib21","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2020-217948","article-title":"Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies","volume":"79","author":"Sanchez-Piedra","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102778","article-title":"Clinical outcomes of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis of global data","volume":"20","author":"Xu","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2021.102687_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102580","article-title":"A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center","volume":"117","author":"Sarmiento-Monroy","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102687_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10654-021-00732-w","article-title":"Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study","volume":"36","author":"Bergman","year":"2021","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.jaut.2021.102687_bib25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"80","author":"Akiyama","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20962692","article-title":"Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents","volume":"13","author":"Fernandez-Gutierrez","year":"2021","journal-title":"Ther. Adv. Musculoskelet Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/annrheumdis-2020-217627","article-title":"Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China","volume":"79","author":"Ye","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.anai.2020.07.023","article-title":"Smell loss is a prognostic factor for lower severity of coronavirus disease 2019","volume":"125","author":"Foster","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"year":"2021","series-title":"COVID-19 Anosmia and Gustatory Symptoms as a Prognosis Factor: a Subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry. Infection","author":"Porta-Etessam","key":"10.1016\/j.jaut.2021.102687_bib29"},{"key":"10.1016\/j.jaut.2021.102687_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19741-6","article-title":"Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission","volume":"11","author":"Peckham","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2021.102687_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001461","article-title":"High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry","volume":"7","author":"Marques","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2021.102687_bib32","article-title":"Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study","volume":"371","author":"Eythorsson","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jaut.2021.102687_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14627","article-title":"The risk for severe COVID 19 in patients with autoimmune and\/or inflammatory diseases: first wave lessons","volume":"34","author":"Druyan","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jaut.2021.102687_bib34","first-page":"527","article-title":"Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102473","article-title":"Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience","volume":"112","author":"Sun","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102687_bib36","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2021.102687_bib37","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102632","article-title":"Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark","volume":"120","author":"Kjeldsen","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102687_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41584-020-00562-2","article-title":"Rheumatic disease and COVID-19: epidemiology and outcomes","volume":"17","author":"Hyrich","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2021.102687_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101657","article-title":"Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: epidemiology and outcomes","volume":"35","author":"Grainger","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2021.102687_bib41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMc2009567","article-title":"Covid-19 in immune-mediated inflammatory diseases - case series from New York","volume":"383","author":"Haberman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2021.102687_bib42","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1016\/S2665-9913(20)30270-8","article-title":"B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.jaut.2021.102687_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab175","article-title":"Timing of Rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis","author":"Quartuccio","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2021.102687_bib44","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3899\/jrheum.200755","article-title":"Risk of severe coronavirus infection (COVID-19) in patients with inflammatory rheumatic diseases","volume":"48","author":"Bachiller-Corral","year":"2021","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2021.102687_bib45","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2021.4385","article-title":"Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"Jama"},{"key":"10.1016\/j.jaut.2021.102687_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102649","article-title":"A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine","author":"Moutsopoulos","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102687_bib47","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13075-021-02414-0","article-title":"The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus","volume":"23","author":"Mai","year":"2021","journal-title":"Arthritis Res. Ther."},{"issue":"Suppl 118","key":"10.1016\/j.jaut.2021.102687_bib49","first-page":"185","article-title":"Type I interferon signature in Sj\u00f6gren's syndrome: pathophysiological and clinical implications","volume":"37","author":"Marketos","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2021.102687_bib50","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/BOR.0000000000000653","article-title":"Interferon-signature in idiopathic inflammatory myopathies","volume":"31","author":"Gallay","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2021.102687_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.08.026","article-title":"The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy","volume":"141","author":"Cooles","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2021.102687_bib52","first-page":"370","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jaut.2021.102687_bib53","first-page":"370","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jaut.2021.102687_bib54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41590-020-00840-x","article-title":"Untuned antiviral immunity in COVID-19 revealed by temporal type I\/III interferon patterns and flu comparison","volume":"22","author":"Galani","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2021.102687_bib55","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.semarthrit.2020.05.001","article-title":"Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs","volume":"50","author":"Michelena","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2021.102687_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102502","article-title":"SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients","volume":"112","author":"Zen","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102687_bib57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s41927-020-00165-0","article-title":"Rheumatic manifestations of COVID-19: a systematic review and meta-analysis","volume":"4","author":"Ciaffi","year":"2020","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.jaut.2021.102687_bib58","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2020-217424","article-title":"Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies","volume":"79","author":"Monti","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib59","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1093\/rheumatology\/kez027","article-title":"Pain and fatigue in primary Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Omdal","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2021.102687_bib60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/ijr.12.4","article-title":"Fatigue in systemic lupus erythematosus","volume":"7","author":"Ahn","year":"2012","journal-title":"Int. J. Clin. Rheumtol."},{"key":"10.1016\/j.jaut.2021.102687_bib61","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/annrheumdis-2020-217566","article-title":"Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib62","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib63","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/22221751.2020.1762515","article-title":"Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients","volume":"9","author":"Sun","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.jaut.2021.102687_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2021.102687_bib65","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2021.102687_bib66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12879-021-06031-9","article-title":"IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays","volume":"21","author":"Shah","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib67","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/S2666-5247(20)30120-8","article-title":"Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study","volume":"1","author":"Wajnberg","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jaut.2021.102687_bib68","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.ijid.2021.03.031","article-title":"The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: a prospective cohort study with multivariate analysis of factors affecting the antibody response","volume":"105","author":"Ba\u015faran","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib69","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2020-219808","article-title":"SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease","volume":"80","author":"D\u2019Silva","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib70","article-title":"Correspondence on \u2018SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease\u2019","author":"C","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102687_bib71","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gutjnl-2021-324388","article-title":"Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841121000950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841121000950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:30:39Z","timestamp":1760257839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841121000950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":71,"alternative-id":["S0896841121000950"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2021.102687","relation":{},"ISSN":["0896-8411"],"issn-type":[{"type":"print","value":"0896-8411"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2021.102687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102687"}}